After Allergan Merger Halt, Vaccines a Focus for Pfizer

New U.S. Treasury regulation has dissuaded Pfizer from its planned merger with Ireland-based Allergan. The two companies agreed on Tuesday to terminate the deal. The tax inversion move would have benefited Pfizer’s profitability and reintroduced the company to the dermatologics market. Pfizer will now consider business divestitures in order to boost its profits. Pfizer previously spun-off its animal health business in 2013, which now operates as the veterinary pharmaceuticals and diagnostics com...